Table 1.
Baseline Information and Demographics
| Study Cohort (N=924) | |
|---|---|
| Age (years) | 59 (45, 70) |
| Female sex; n (%) | 579 (64.0) |
| Body mass index (kg/m2) | 26.2 (23.1, 30.2) |
| Duration of symptoms; months† | 12 (5, 36) |
| Previous oral steroid use; n (%) | 45 (5.1) |
| Fracture on pre-injection imaging; n (%) | 17 (1.8) |
| History of autoimmune disease; n (%) | 149 (16.1) |
| History of allergies; n (%) | 473 (51.2) |
| Additional injections; n (%) | 202 (21.9) |
| Laterality | |
| Bilateral | 43 (4.7) |
| Left | 413 (44.7) |
| Right | 468 (50.6) |
| Guidance | |
| Fluoroscopic | 334 (36.1) |
| Ultrasound | 590 (63.9) |
| Type of steroid in injectate‡ | |
| Triamcinolone | 479 (51.8) |
| Methylprednisolone | 377 (40.8) |
| Betamethasone | 64 (6.9) |
| Dexamethasone | 4 (0.4) |
Results are median (interquartile range), unless otherwise specified.
†
Duration of symptoms was available for 449 patients.
‡
Steroid doses ranges from 3–12 mg for betamethasone, 40–120 mg for methylprednisolone, and 20–40 mg for triamcinolone. For dexamethasone, all 4 patients received 4 mg.